Terms: = Bone cancer AND TG, Thyroglobulin AND Prognosis
36 results:
1. LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism.
Cai F; Liu L; Bo Y; Yan W; Tao X; Peng Y; Zhang Z; Liao Q; Yi Y
BMC Cancer; 2024 Feb; 24(1):166. PubMed ID: 38308235
[TBL] [Abstract] [Full Text] [Related]
2. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
Karkeet RM; Zekri AN; Sayed-Ahmed MM; Sherif GM; Salem SE; Abdelbary A; Fouad MA; Saad SY
PLoS One; 2022; 17(12):e0278282. PubMed ID: 36480560
[TBL] [Abstract] [Full Text] [Related]
3. [Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis].
Gao WB; Shi MJ; Zhang HY; Wu CB; Zhu JH
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Oct; 53(5):921-927. PubMed ID: 34650295
[TBL] [Abstract] [Full Text] [Related]
4. A cutoff thyroglobulin value suggestive of distant metastases in differentiated thyroid cancer patients.
Couto JS; Almeida MFO; Trindade VCG; Marone MMS; Scalissi NM; Cury AN; Ferraz C; Padovani RP
Braz J Med Biol Res; 2020; 53(11):e9781. PubMed ID: 33053096
[TBL] [Abstract] [Full Text] [Related]
5. Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea.
Yoon JH; Jeon MJ; Kim M; Hong AR; Kim HK; Shin DY; Kim BH; Kim WB; Shong YK; Kang HC
PLoS One; 2020; 15(8):e0238207. PubMed ID: 32841270
[TBL] [Abstract] [Full Text] [Related]
6. Development of an ENPP1 Fluorescence Probe for Inhibitor Screening, Cellular Imaging, and Prognostic Assessment of Malignant Breast cancer.
Kawaguchi M; Han X; Hisada T; Nishikawa S; Kano K; Ieda N; Aoki J; Toyama T; Nakagawa H
J Med Chem; 2019 Oct; 62(20):9254-9269. PubMed ID: 31536342
[TBL] [Abstract] [Full Text] [Related]
7. Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases.
Zunino A; Pitoia F; Faure E; Reyes A; Sala M; Sklate R; Ilera V; Califano I;
Endocrine; 2019 Sep; 65(3):630-636. PubMed ID: 31327159
[TBL] [Abstract] [Full Text] [Related]
8. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.
Zhang XY; Sun JW; Qiu ZL; Wang Y; Chen XY; Zhao JH; Luo QY
Endocrine; 2019 Nov; 66(2):254-265. PubMed ID: 31317522
[TBL] [Abstract] [Full Text] [Related]
9. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological features of low-grade malignant endolymphatic sac tumors.
Wang HQ; Jie L; Shi HY
Pathol Res Pract; 2018 Mar; 214(3):431-435. PubMed ID: 29482989
[TBL] [Abstract] [Full Text] [Related]
11. Lung adenocarcinoma with thyroid metastasis: a case report.
Dao A; Jabir H; Taleb A; Benchakroun N; Bouchbika Z; Nezha T; Jouhadi H; Sahraoui S; Benider A
BMC Res Notes; 2017 Mar; 10(1):130. PubMed ID: 28327204
[TBL] [Abstract] [Full Text] [Related]
12. Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma.
Choi YM; Kim WG; Kwon H; Jeon MJ; Lee JJ; Ryu JS; Hong EG; Kim TY; Shong YK; Kim WB
Eur J Endocrinol; 2016 Sep; 175(3):165-72. PubMed ID: 27272238
[TBL] [Abstract] [Full Text] [Related]
13. Cytologic Features and Immunocytochemical Profiles of Malignant Effusions with Metastatic Papillary Thyroid Carcinoma: A Case Series from a Single Institution.
Lew M; Pang JC; Roh MH; Jing X
Acta Cytol; 2015; 59(5):412-7. PubMed ID: 26587773
[TBL] [Abstract] [Full Text] [Related]
14. Is it practical and cost effective to detect differentiated thyroid carcinoma metastases by (18)F-FDG PET/CT, by (18)F-FDG SPET/CT or by (131)I SPET/CT?
He X; Wang X; Yu J; Ma C
Hell J Nucl Med; 2015; 18(1):2-4. PubMed ID: 25679071
[TBL] [Abstract] [Full Text] [Related]
15. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS; Nutting CM; Jarzab B; Elisei R; Siena S; Bastholt L; de la Fouchardiere C; Pacini F; Paschke R; Shong YK; Sherman SI; Smit JW; Chung J; Kappeler C; Peña C; Molnár I; Schlumberger MJ;
Lancet; 2014 Jul; 384(9940):319-28. PubMed ID: 24768112
[TBL] [Abstract] [Full Text] [Related]
16. Reconstruction using a frozen tumor-bearing vertebra in total en bloc spondylectomy can enhance antitumor immunity.
Murakami H; Kato S; Ueda Y; Fujimaki Y; Tsuchiya H
Eur Spine J; 2014 May; 23 Suppl 2():222-7. PubMed ID: 24097232
[TBL] [Abstract] [Full Text] [Related]
17. Pelvic pain and papillary thyroid carcinoma: case report.
Del Rio P; De Simone B; Robuschi G; Sianesi M
Ann Ital Chir; 2013; 84(3):347-50. PubMed ID: 23857214
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer.
Qiu ZL; Song HJ; Xu YH; Luo QY
J Clin Endocrinol Metab; 2011 Oct; 96(10):3078-86. PubMed ID: 21795449
[TBL] [Abstract] [Full Text] [Related]
19. Primary strumal carcinoid tumor of the ovary with multiple bone and breast metastases.
Kurabayashi T; Minamikawa T; Nishijima S; Tsuneki I; Tamura M; Yanase T; Hashidate H; Shibuya H; Motoyama T
J Obstet Gynaecol Res; 2010 Jun; 36(3):567-71. PubMed ID: 20598039
[TBL] [Abstract] [Full Text] [Related]
20. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.
Asioli S; Erickson LA; Sebo TJ; Zhang J; Jin L; Thompson GB; Lloyd RV
Am J Surg Pathol; 2010 Jan; 34(1):44-52. PubMed ID: 19956062
[TBL] [Abstract] [Full Text] [Related]
[Next]
